Vaxcyte Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
PCVX$66.36-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance — December 31, 2021 | 53,031,978 | $56 | $582,844 | $(298,641) | $(241) | $284,018 | |||||
| Issuance of common stock and pre-funded warrants in connection with public follow-on offerings, net of issuance costs of $45,814 | 21,062,500 | 21 | 759,160 | — | — | 759,181 | |||||
| Issuance of common stock in connection with at-the-market offering, net of issuance costs of $3,107 | 3,921,528 | 4 | 97,295 | — | — | 97,299 | |||||
| Issuance of common stock for Sutro stock payment | 167,780 | — | 7,995 | — | — | 7,995 | |||||
| Issuance of common stock in connection with employee incentive plans | 1,286,884 | 1 | 5,935 | — | — | 5,936 | |||||
| Taxes paid related to the net share settlement of equity awards | — | — | (861) | — | — | (861) | |||||
| Stock-based compensation expense | — | — | 23,650 | — | — | 23,650 | |||||
| Other comprehensive loss | — | — | — | — | (120) | (120) | |||||
| Net loss | — | — | — | (223,485) | — | (223,485) | |||||
| Balance — December 31, 2022 | 79,470,670 | $82 | $1,476,018 | $(522,126) | $(361) | $953,613 | |||||
| Issuance of common stock and pre-funded warrants in connection with public follow-on offerings, net of issuance costs of $29,952 | 13,030,000 | 13 | 545,289 | — | — | 545,302 | |||||
| Issuance of common stock in connection with at-the-market offering, net of issuance costs of $2,237 | 2,095,943 | 2 | 90,739 | — | — | 90,741 | |||||
| Issuance of common stock in connection with employee incentive plans | 768,218 | 1 | 7,653 | — | — | 7,654 | |||||
| Taxes paid related to the net share settlement of equity awards | — | — | (3,876) | — | — | (3,876) | |||||
| Stock-based compensation expense | — | — | 48,760 | — | — | 48,760 | |||||
| Other comprehensive loss | — | — | — | — | 540 | 540 | |||||
| Net loss | — | — | — | (402,266) | — | (402,266) | |||||
| Balance — December 31, 2023 | 95,364,831 | $98 | $2,164,583 | $(924,392) | $179 | $1,240,468 | |||||
| Issuance of common stock in connection with employee incentive plans | 2,122,953 | 2 | 27,142 | — | — | 27,144 | |||||
| Issuance of common stock and pre-funded warrants in connection with public follow-on offerings, net of issuance costs of $117,785 | 24,782,690 | 25 | 2,239,688 | — | — | 2,239,713 | |||||
| Issuance of common stock in connection with at-the-market offering, net of commissions and offering expenses of $4,393 | 2,622,560 | 3 | 195,940 | — | — | 195,943 | |||||
| Taxes paid related to the net share settlement of equity awards | — | — | (14,292) | — | — | (14,292) | |||||
| Stock-based compensation expense | — | — | 84,822 | — | — | 84,822 | |||||
| Other comprehensive loss | — | — | — | — | (4,052) | (4,052) | |||||
| Net loss | — | — | — | (463,927) | — | (463,927) | |||||
| Balance — December 31, 2024 | 124,893,034 | $128 | $4,697,883 | $(1,388,319) | $(3,873) | $3,305,819 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.